Dear Colleagues,

With a great deal of optimistic enthusiasm, I take the pleasure of connecting with you through this February 2015 edition of Oviya MedSafe’s newsletter! Quite a lot of development has brewed at our end during the first few weeks of 2015, about which I am happy to share with you today.  

Subsequent to the successful launch of Oviya MedSafe's revamped website which went on to get positive reviews from industry colleagues, our maiden initiative in the United States - a well-received Tabletop Exhibit at the DIA's Pharmacovigilance and Risk Management Strategies 2015 conference held at Washington DC between January 26 and 28, has added the next feather to our cap.

Not only the exhibition at the conference, but Oviya MedSafe's East Coast USA expedition too was quite productive, in spite of the logistic hurdles posed by Winter Storm Juno. Our business meetings with prospective clients have refined our understanding of the pharmacovigilance service needs of the North American market and as a result, we have further streamlined our offerings to fulfil the drug safety obligations of pharmaceutical companies and biotechnology firms, in the North American region.

Meanwhile, a quick look at the recent happenings in the pharmacovigilance scenario in India indicates that the voyage is in the right direction, with the need to sensitize physicians on ADRs to strengthen pharmacovigilance in India being highlighted by the Drug Controller General of India and with the proposal to identify more AMCs for access to WHO database through Vigiflow software as part of PvPI being mooted. It is worthy to note that the US FDA is now increasing its staff strength in India and is also inviting host-country regulators for its inspections to create more awareness about its ways.

Personally, the New Year has been kind to me, as I have been showered with a string of recognitions starting with the award of the Fellowship of the Pharmaceutical Information and Pharmacovigilance Association (FPIPA), in line with the eligibility criteria set by PIPA as a professional accreditation association. While I am thrilled to be the first person hailing from India to receive this fellowship, I believe I owe a lot to my seniors in the industry on whose pedestal of achievement my statue of appreciation stands. The news about this recognition and my interview were published in several news portals such as Express Pharma, The Pharma Times, Pharmabiz, Life Science World, etc, whom I would like to thank at this juncture.

Secondly, a mention of Oviya MedSafe and my comment on the growth of the Pharmacovigilance Outsourcing industry in India were made in the Wall Street Journal on 01-Feb-2015 in the article titled New Outsourcing Frontier in India: Monitoring Drug Safety, much to the acclaim of our well-wishers and peers.

Last but not the least; I have been elected the Chair of the newly formed Pharmacovigilance Council of the Indian Society for Clinical Research, which was announced at the 8th Annual Conference of the association held at Gurgaon, India on February 13 and 14, 2015. While I accept this new responsibility, it is my privilege to reiterate my continuous commitment to the advancement of pharmacovigilance, which I am always passionate about.

Before signing off, I would like to thank you for taking the time to read this newsletter edition and request you to share it with anybody whom you think may be interested in pharmacovigilance.

Looking forward to meeting you through our March 2015 newsletter edition,
 

With thanks & regards, 
Dr J Vijay Venkatraman 
MBBS, F. Diab., MBA 

Managing Director & CEO, 
Oviya MedSafe 
Pharmacovigilance Consulting & Drug Safety Services
Coimbatore, India & London, UK

India Office: +91-422-2444442
UK Office:    +44-8452-733839 

Website: www.oviyamedsafe.com 
Facebook: www.facebook.com/OviyaMedSafe 
Google Plus: plus.google.com/109414464810448488118/posts
Twitter: www.twitter.com/OviyaMedSafe 
LinkedIn: www.linkedin.com/company/oviya-medsafe